Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
News headline image
2 Signals to Watch Before Buying SAVA Stock ↗
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play. 
Via InvestorPlace
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results ↗
Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring. 
Via InvestorPlace
News headline image
Why Is Acumen (ABOS) Stock Up 95% Today? ↗
Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company. 
Via InvestorPlace
News headline image
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗
 
Via Benzinga
News headline image
Why Is Biogen (BIIB) Stock Up 40% Today? ↗
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors. 
Via InvestorPlace
News headline image
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal ↗
 
Via Benzinga
News headline image
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact ↗
 
Via Benzinga
News headline image
Why Acumen Pharmaceuticals Stock Is Soaring Today ↗
Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink: 
Via Benzinga
News headline image
Why Is Cassava Sciences (SAVA) Stock Heating Up Today? ↗
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target. 
Via InvestorPlace
News headline image
Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28 ↗
Bloomberg 
Via Benzinga
News headline image
What In The World Is Going On With Biogen (BIIB) Shares? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co. 
Via Benzinga
News headline image
Why Cassava Sciences Shares Are Soaring Higher ↗
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co. 
Via Benzinga
News headline image
Why Biogen Stock Is Up 40% Today ↗
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday. 
Via Benzinga
News headline image
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
Via Benzinga
News headline image
US Stock Futures Down Ahead Of Fed Speakers, Economic Data ↗
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh... 
Via Benzinga
News headline image
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock ↗
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. 
Via Benzinga
News headline image
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer ↗
 
Via Benzinga
News headline image
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment ↗
Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab ↗
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
News headline image
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer ↗
The  
Via Benzinga
News headline image
News-Filled Day ↗
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Hopes For A Peace Accord ↗
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.